Accessibility Menu
MediWound logo

MediWound(NASDAQ) MDWD

Market Cap$181.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-88%
5 Year-47%
1 Year-24%
1 Month-5%
$14.09
-0.07%
-0.01Today
After hours$14.16+$0.07 (+0.50%)
MediWound last closing stock price
MetricPriceDate
Last closeUSD 14.122026-07-31
MediWound stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.77%USD 14.232026-07-24
1 month-4.72%USD 14.822026-07-01
3 month-15.09%USD 16.632026-05-01
Year to date-23.51%USD 18.462025-12-31
1 year-24.25%USD 18.642025-07-31
3 year+47.08%USD 9.602023-08-01
5 year-46.92%USD 26.602021-07-30
Since inception-88.32%USD 120.892014-03-20

MediWound Financials at a Glance

Market Cap

$181.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$14.48M

Net Income (TTM)

-$26.11M

EPS (TTM)

-$2.26

P/E Ratio

-6.25

Dividend

$0.00

Beta (Volatility)

0.75 (Low)

Price

$14.09

Volume

75,362

Open

$14.10

Previous Close

$14.12

Daily Range

$13.91 - $14.57

52-Week Range

$13.54 - $20.30

Estimated Earnings Date

Aug 13, 2026

MDWD News

featured-earnings-leadership-highlights.png

MediWound Revenue Jumps 43% in Q2

Motley Fool Markets TeamAug 14, 2025
longview3_large_large_large_large

Wednesday’s Top Health Care Stories: Pfizer, AstraZeneca, MediWound, and Gilead Sciences

Leo SunMay 21, 2014

MDWD: Motley Fool Moneyball Superscore

54

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MediWound

MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative bio-therapeutic solutions for tissue repair and regeneration. The company operates in the United States, Germany, Italy, Spain, and other international markets, offering products designed to address critical medical needs in wound care.

Products and Services
  • NexoBrid: A biopharmaceutical product for removing eschar in burn patients
  • EscharEx: A bromelain-based therapy for chronic and hard-to-heal wounds
  • MW005: A biological product candidate for treating non-melanoma skin cancers
Growth Outlook
  • Recent partnerships enhance market access and distribution capabilities
  • Expansion into new international markets is underway
  • Ongoing clinical trials may lead to new product approvals
Financial Highlights
  • Q1 2026 revenue of $1.475 million, showing a strategic focus on growth
  • Cash and cash equivalents of $44.646 million as of March 31, 2026
  • Trailing twelve months (TTM) gross profit margin of 19.61%
MediWound Ltd. is positioned in the biotechnology sector, focusing on innovative solutions for wound care. The company’s flagship product, NexoBrid, addresses a significant medical need in burn treatment, while EscharEx and MW005 target chronic wounds and skin cancers, respectively. The company has demonstrated a commitment to growth through strategic partnerships and market expansion, which may enhance its competitive position. Recent financial data indicates a revenue of $1.475 million for the first quarter of 2026, reflecting ongoing efforts to increase market penetration. The company maintains a strong cash position with $44.646 million in cash and cash equivalents, providing a solid foundation for future investments and operational needs. The TTM gross profit margin of 19.61% suggests effective cost management and potential for profitability as the company scales its operations. Overall, MediWound Ltd. presents a compelling opportunity in the biopharmaceutical space, with a focus on innovative wound care solutions and a strategic approach to growth.
AI Generated • Jul 28, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

121

CEO

Ofer Gonen

Website

www.mediwound.com

Headquarters

Yavne, HM 8122745, IL

MDWD Financials

Key Financial Metrics (TTM)

Gross Margin

19.61%

Operating Margin

-193.62%

Net Income Margin

-180.30%

Return on Equity

-67.22%

Return on Capital

-48.82%

Return on Assets

-32.64%

Earnings Yield

-16.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$181.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.85M

Volume

75.36K

Avg. Volume

89.26K

Financials (TTM)

Gross Profit

$2.84M

Operating Income

-$28.03M

EBITDA

-$14.84M

Operating Cash Flow

-$18.77M

Capital Expenditure

-$6.37M

Free Cash Flow

-$25.13M

Cash & ST Invst.

$44.65M

Total Debt

$8.13M

MediWound Performance Analysis

MediWound annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 26,496,00011.5%
20232023-12-31USD 18,686,000-29.5%
20242024-12-31USD 20,222,0008.2%
20252025-12-31USD 16,959,000-16.1%
MediWound sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3044.3%
Q32025-09-30-4.9%
Q42025-12-31-65.6%
Q12026-03-31-21.0%
MediWound annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.9312.9%
20232023-12-31USD -0.75-81.0%
20242024-12-31USD -3.03307.3%
20252025-12-31USD -2.10-30.8%
MediWound sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-1730.4%
Q32025-09-3080.5%
Q42025-12-31-133.3%
Q12026-03-3158.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$1.48M

-62.7%

Gross Profit

$323.00K

-56.2%

Gross Margin

21.90%

N/A

Market Cap

$181.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.50M

N/A

Employees

121

N/A

Net Income

-$2.95M

-306.6%

EBITDA

-$2.59M

-613.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$44.65M

+16.7%

Total Debt

$8.13M

+26.5%

Accounts Receivable

$2.75M

-46.9%

Inventory

$4.77M

+33.3%

Long Term Debt

$8.13M

+26.5%

Short Term Debt

$929.00K

N/A

Return on Assets

-32.64%

N/A

Return on Invested Capital

-48.06%

N/A

Free Cash Flow

-$8.57M

-69.1%

Operating Cash Flow

-$6.75M

-64.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IVVDInvivyd, Inc.
$0.54-8.01%
EPRXEupraxia Pharmaceuticals Inc.
$6.40-2.29%
AARDAardvark Therapeutics, Inc. Common Stock
$6.60+3.13%
TARAProtara Therapeutics, Inc.
$3.92-2.73%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About MDWD

What is the current price of MediWound?

MediWound is trading at $14.12 per share.

What is the 52-week range for MediWound?

Over the past 52 weeks, MediWound has traded between $13.54 and $20.30.

How much debt does MediWound have?

As of the most recent reporting period, MediWound reported total debt of $9.06M.

How much cash does MediWound have on hand?

MediWound reported $44.65M in cash and cash equivalents in its most recent financial results.

What is MediWound’s dividend yield?

MediWound does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services